Skip to content

Effect of Jin three-needle therapy on quality of life in patients of Parkinson Disease: a multicenter randomized controlled study

Effect of Jin three-needle therapy on quality of life in patients of Parkinson Disease: a multicenter randomized controlled study

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17013201
Enrollment
Unknown
Registered
2017-11-01
Start date
2016-10-10
Completion date
Unknown
Last updated
2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Interventions

Treatment group:Acupuncture,Madopar

Sponsors

College of TCM, Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients conform to the diagnostic criteria of PD; 2. Aged between 40 and 75 years old; 3. conform to the classification criteria of PD: The stage of revised Hoehn-Yahr Scale between I-III levels; 4. inpatients or outpatients of follow-up; 5. The initial patient, without any treatment of the Parkinson Disease; 6. receive the treatments voluntarily and sign informed consent form.;Inclusion criteria: 1. Patients conform to the diagnostic criteria of PD; 2. Aged between 40 and 75 years old; 3. conform to the classification criteria of PD: The stage of revised Hoehn-Yahr Scale between I-III levels; 4. inpatients or outpatients of follow-up; 5. The initial patient, without any treatment of the Parkinson Disease; 6. receive the treatments voluntarily and sign informed consent form.;Inclusion criteria: 1. Patients conform to the diagnostic criteria of PD; 2. Aged between 40 and 75 years old; 3. conform to the classification criteria of PD: The stage of revised Hoehn-Yahr Scale between I-III levels; 4. inpatients or outpatients of follow-up; 5. The initial patient, without any treatment of the Parkinson Disease; 6. receive the treatments voluntarily and sign informed consent form.;Inclusion criteria: 1. Patients conform to the diagnostic criteria of PD; 2. Aged between 40 and 75 years old; 3. conform to the classification criteria of PD: The stage of revised Hoehn-Yahr Scale between I-III levels; 4. inpatients or outpatients of follow-up; 5. The initial patient, without any treatment of the Parkinson Disease; 6. receive the treatments voluntarily and sign informed consent form.;Inclusion criteria: 1. Patients conform to the diagnostic criteria of PD; 2. Aged between 40 and 75 years old; 3. conform to the classification criteria of PD: The stage of revised Hoehn-Yahr Scale between I-III levels; 4. inpatients or outpatients of follow-up; 5. The initial patient, without any treatment of the Parkinson Disease; 6. receive the treatments voluntarily and sign informed consent form.

Exclusion criteria

Exclusion criteria: 1. secondary Parkinson's disease; 2. Participants with severe primary disease of the cardiovascular, hepatic, renal, or hematopoietic system; 3. patients with a simultaneous psychiatric or other severe disease; 4. Participants who are allergic to the Madopar or Acupuncture.;Exclusion criteria: 1. secondary Parkinson's disease; 2. Participants with severe primary disease of the cardiovascular, hepatic, renal, or hematopoietic system; 3. patients with a simultaneous psychiatric or other severe disease; 4. Participants who are allergic to the Madopar or Acupuncture.;Exclusion criteria: 1. secondary Parkinson's disease; 2. Participants with severe primary disease of the cardiovascular, hepatic, renal, or hematopoietic system; 3. patients with a simultaneous psychiatric or other severe disease; 4. Participants who are allergic to the Madopar or Acupuncture.;Exclusion criteria: 1. secondary Parkinson's disease; 2. Participants with severe primary disease of the cardiovascular, hepatic, renal, or hematopoietic system; 3. patients with a simultaneous psychiatric or other severe disease; 4. Participants who are allergic to the Madopar or Acupuncture.;Exclusion criteria: 1. secondary Parkinson's disease; 2. Participants with severe primary disease of the cardiovascular, hepatic, renal, or hematopoietic system; 3. patients with a simultaneous psychiatric or other severe disease; 4. Participants who are allergic to the Madopar or Acupuncture.

Design outcomes

Primary

MeasureTime frame
UPDRS;Modified Webster;Berg balance scale;PDQ-39;Beck Anxiety Inventory;Beck Depression Inventory;TESS;

Secondary

MeasureTime frame
HAMD;HAMA;SDS;PDSS;

Countries

China

Contacts

Public ContactHuang Yong;Huang Yong;Huang Yong;Huang Yong;Huang Yong ;;;;

College of TCM, Southern Medical University;College of TCM, Southern Medical University;College of TCM, Southern Medical University;College of TCM, Southern Medical University;College of TCM, Southern Medical University

nfhy@fimmu.com;nfhy@fimmu.com;nfhy@fimmu.com;nfhy@fimmu.com;nfhy@fimmu.com+86 13719189644;+86 13719189644;+86 13719189644;+86 13719189644;+86 13719189644

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026